Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa

Background: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) has become a major therapeutic problem worldwide. Combination therapy may be an alternative chemotherapeutic option. Methods: Bioluminescent CRPA Xen5-D9 was developed in the present study. Minimum inhibitory concentration (MIC) of amikacin (AMK) or cefoperazone/sulbactam (SCF) against CRPA Xen5-D9 was determined by microdilution method. CRPA Xen5-D9 was intraperitoneally injected to establish a mouse model of intraperitoneal infection.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Source Type: research